References
- Clissold SP, Campoli-Richards DM. Omeprazole-an updated review. Drugs 1990; 32: 15–47
- Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 1991; 36: 1665–9
- Andersson T, Regardt CG, Dahl-Puustinen ML, Bertilson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415–6
- Petersen KU. Review article: omeprazole and the cytochrome P-450 system. Aliment Pharmacol Ther 1995; 9: 1–9
- Gugler R, Jensen J. Omeprazole inhibits oxidative drug metabolism. Gastroenterology 1985; 89: 1, 1235
- Pritchard PJ, Walt RP, Kitchingman GK, Somerville KW, Langman MJS, Williams J, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543–5
- Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79–85
- Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 1990; 12: 329–33
- Unge P, Svedberg L-E, Nordgren A, Blom H, Andersson T, Lagerstrom PO, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509–12
- Sutfin T, Balmer K, Boström H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176–84
- Hermans JJR, Thijssen HHW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol. P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993; 110: 482–90
- Thijssen HH, Janssen GMJ, Baars LGM. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol 1986; 30: 619–23
- Duursema L, Muller FO, Schall R, Middle MV, Hundt HKL, Groenewoud G, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995; 39: 700–3
- de Hoon JNJM, Thijssen HHW, Beysens AJMM, van Bortel LMAB. Study on the interaction between omeprazole and acenocoumarol. Neth J Med 1997; 50: A9
- Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743–52
- Andersson T, Regärdt CG, Lou YC, Zhang Y, Dahl Puustinen ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25–31
- Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662–9
- Hirsh J. Oral anticoagulant drugs. N Engl J Med 1971; 324: 1865–75
- Landefeld CS, Beyth RJ. Anticoagulation-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315–328
- Wells PS, Holbrook AM, Crowther NR, Hirsch J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676–83